Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
Dec 02, 2024 10:34 HKT |  |
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Nov 30, 2024 21:08 HKT |  |
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Nov 30, 2024 20:34 HKT | |
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL)
Nov 29, 2024 10:48 HKT | |
|
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea
Nov 19, 2024 17:37 HKT | |
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area
Oct 25, 2024 11:28 HKT | |
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award'
Oct 25, 2024 09:18 HKT | |
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024
Oct 25, 2024 08:57 HKT |  |
|
T.MAN Pharmaceutical PCL (SET: TMAN) Showcases Leadership in Health Innovation, Aiming for Sustainable Growth Following Listing on SET
Oct 23, 2024 09:00 HKT |  |
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial
Oct 22, 2024 11:52 HKT | |
|
Acrometa Group to Divest Its Life Sciences Business, Pursue New Business Opportunities in the Region
Oct 21, 2024 22:50 HKT |  |
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy
Oct 21, 2024 12:19 HKT | |
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery
Oct 18, 2024 18:37 HKT | |
|
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
Oct 17, 2024 08:00 HKT |  |
|
CanSino Receives Another Strong Boost
Oct 09, 2024 19:29 HKT | |
|
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis
Sep 25, 2024 21:00 HKT |  |
|
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
Sep 17, 2024 20:30 HKT |  |
|
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)
Sep 11, 2024 11:34 HKT | |
|
Hua Medicine Announces 2024 Interim Results
Aug 30, 2024 11:40 HKT | |
|
CanSinoBIO Reports Outstanding H1 2024 Performance
Aug 29, 2024 22:23 HKT | |
|